Cited by 678Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Shigematsu, Hisayuki, Takahashi, Takao, Nomura, Masaharu, Majmudar, Kuntal, Suzuki, Makoto, Lee, Huei, Wistuba, Ignacio I., Fong, Kwun M., Toyooka, Shinichi, Shimizu, Nobuyoshi, Fujisawa, Takehiko, Minna, John D., Gazdar, Adi F.·2005·Cancer Research

DOI 10.1158/0008-5472.can-04-4235

Open this paper in CoChat — free account

Abstract

Mutations in the epidermal growth factor receptor gene (EGFR) in lung cancers predict for sensitivity to EGFR kinase inhibitors. HER2 (also known as NEU, EGFR2, or ERBB2) is a member of the EGFR family of receptor tyrosine kinases and plays important roles in the pathogenesis of certain human cancers, and mutations have recently been reported in lung cancers. We sequenced the tyrosine kinase domain of HER2 in 671 primary non-small cell lung cancers (NSCLC), 80 NSCLC cell lines, and 55 SCLCs and other neuroendocrine lung tumors as well as 85 other epithelial cancers (breast, bladder, prostate, and colorectal cancers) and compared the mutational status with clinicopathologic features and the presence of EGFR or KRAS mutations. HER2 mutations were present in 1.6% (11 of 671) of NSCLC and were absent in other types of cancers. Only one adenocarcinoma cell line (NCI-H1781) had a mutation. All HER2 mutations were in-frame insertions in exon 20 and target the identical corresponding region as did EGFR insertions. HER2 mutations were significantly more frequent in never smokers (3.2%, 8 of 248; P=0.02) and adenocarcinoma histology (2.8%, 11 of 394; P=0.003). In 394 adenocarcinoma cases, HER2 mutations preferentially targeted Oriental ethnicity (3.9%) compared with other ethnicities (0.7%), female gender (3.6%) compared with male gender (1.9%) and never smokers (4.1%) compared with smokers (1.4%). Mutations in EGFR, HER2, and KRAS genes were never present together in individual tumors and cell lines. The remarkable similarities of mutations in EGFR and HER2 genes involving tumor type and subtype, mutation type, gene location, and specific patient subpopulations targeted are unprecedented and suggest similar etiologic factors. EGFR, HER2, and KRAS mutations are mutually exclusive, suggesting different pathways to lung cancer in smokers and never smokers.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-04-4235

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W. J., Jones, L. A., Holt, J. A., Wong, S., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J. A., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,817
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J., Lydon, N., Kantarjian, H. M., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,237
Revisions in the International System for Staging Lung Cancer
Mountain, C. F. (1997) · CHEST Journal · doi:10.1378/chest.111.6.1710 · Cited by 4,565
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation

Show all 28 references

Sorted by citations

Items 101–200 of 678

MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
Kubo, T., Yamamoto, H., Lockwood, W. W., Valencia, I., Soh, J., Peyton, M., Jida, M., Otani, H., Fujii, T., Ouchida, M., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.24150 · Cited by 143
Self-citation
Characteristics of Lung Cancers Harboring NRAS Mutations
Ohashi, K., Sequist, L. V. D., Arcila, M. E., Lovly, C. M., Chen, X., Rudin, C. M., Morán, T., Camidge, D. R., Vnencak‐Jones, C. L., Berry, L. D., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3173 · Cited by 147
The Role of Human Epidermal Growth Factor Receptor 2 as a Prognostic Factor in Lung Cancer: A Meta-Analysis of Published Data
Liu, L., Shao, X., Gao, W., Bai, J., Wang, R., Huang, P., Yin, Y., Liu, P., & Shu, Y. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f26266 · Cited by 140
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 147
Non–Small-Cell Lung Cancer and Ba/F3 Transformed Cells Harboring the ERBB2 G776insV_G/C Mutation Are Sensitive to the Dual-Specific Epidermal Growth Factor Receptor and ERBB2 Inhibitor HKI-272
Shimamura, T., Ji, H., Minami, Y., Thomas, R. K., Lowell, A. M., Shah, K., Greulich, H. E., Glatt, K. A., Meyerson, M. M., Shapiro, G. I., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0971 · Cited by 135
EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation
Trowe, T., Boukouvala, S., Calkins, K., Cutler, R. E., Fong, R., Funke, R. P., Gendreau, S. B., Kim, Y. D., Miller, N., Woolfrey, J. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4367 · Cited by 132
Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy
Felip, E., Gridelli, C., Baas, P., Rosell, R., & Stahel, R. A. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr150 · Cited by 134
Novel Therapeutic Targets in Non-small Cell Lung Cancer
Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 133
Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors
Anglesio, M. S., Arnold, J. M., George, J., Tinker, A. V., Tothill, R. W., Waddell, N., Simms, L. A., Locandro, B., Fereday, S., Traficante, N., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0193 · Cited by 133
Molecular genetics of lung cancer in people who have never smoked
Subramanian, J., & Govindan, R. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70174-8 · Cited by 132
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 131
Genomic alterations of ERBB receptors in cancer: clinical implications
Mishra, R., Hanker, A. B., & Garrett, J. T. (2017) · Oncotarget · doi:10.18632/oncotarget.22825 · Cited by 132
High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH
Garnis, C., Lockwood, W. W., Vucic, E. A., Ge, Y., Girard, L., Minna, J. D., Gazdar, A. F., Lam, S. C., MacAulay, C. E., & Lam, W. L. (2005) · International Journal of Cancer · doi:10.1002/ijc.21491 · Cited by 128
Self-citation
Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation ofERBB2rather thanEGFR
Cohen, E. E. W., Lingen, M. W., Martin, L. E., Harris, P. L., Brannigan, B. W., Haserlat, S. M., Okimoto, R. A., Sgroi, D. C., Dahiya, S. M., Muir, B., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0926 · Cited by 128
Exclusive mutation in epidermal growth factor receptor gene, HER‐2, and KRAS, and synchronous methylation of nonsmall cell lung cancer
Suzuki, M., Shigematsu, H., Iizasa, T., Hiroshima, K., Nakatani, Y., Minna, J. D., Gazdar, A. F., & Fujisawa, T. (2006) · Cancer · doi:10.1002/cncr.21853 · Cited by 127
Self-citation
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131
Role of the HER2 [Ile655Val] genetic polymorphism in tumorogenesis and in the risk of trastuzumab-related cardiotoxicity
Beauclair, S., Formento, P., Fischel, J., Lescaut, W., Largillier, R., Chamorey, E., Hofman, P. M., Ferrero, J.-M., Pagès, G., & Milano, G. A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm181 · Cited by 121
Novel Germline Mutation in the Transmembrane Domain of HER2 in Familial Lung Adenocarcinomas
Yamamoto, H., Higasa, K., Sakaguchi, M., Shien, K., Soh, J., Ichimura, K., Furukawa, M., Hashida, S., Tsukuda, K., Takigawa, N., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt338 · Cited by 121
Self-citation
Molecular pathology of lung cancer: current status and perspectives
Oberndorfer, F., & Müllauer, L. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000429 · Cited by 122
Consensus for HER2 alterations testing in non-small-cell lung cancer
Ren, S., Wang, J., Ying, J., Mitsudomi, T., Lee, D., Wang, Z., Chu, Q., Mack, P. C., Cheng, Y., Duan, J., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100395 · Cited by 127
Stratification of non-small cell lung cancer patients for therapy with epidermal growth factor receptor inhibitors: the EGFR fluorescence in situ hybridization assay.
Varella‐Garcia, M. (2006) · Diagnostic Pathology · doi:10.1186/1746-1596-1-19 · Cited by 117
Molecular Pathology of Non–Small Cell Lung Cancer
Aisner, D. L., & Marshall, C. B. (2012) · American Journal of Clinical Pathology · doi:10.1309/ajcpfr12wjkceezz · Cited by 119
Cytoglobin, the Newest Member of the Globin Family, Functions as a Tumor Suppressor Gene
Shivapurkar, N., Stastny, V., Okumura, N., Girard, L., Xie, Y., Prinsen, C., Thunnissen, E., Wistuba, I. I., Czerniak, B. A., Frenkel, E. P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0565 · Cited by 116
Self-citation
Lung cancer molecular epidemiology in China: recent trends.
Zhou, C. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.09.01 · Cited by 115
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
Rothschild, S. I. (2015) · Cancers · doi:10.3390/cancers7020816 · Cited by 117
Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung
Yoshida, Y., Shibata, T., Kokubu, A., Tsuta, K., Matsuno, Y., Kanai, Y., Asamura, H., Tsuchiya, R., & Hirohashi, S. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.04.012 · Cited by 114
The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer
Cardarella, S., Ortiz, T. M., Joshi, V. A., Butaney, M., Jackman, D. M., Kwiatkowski, D. J., Yeap, B. Y., Janne, P. A., Lindeman, N. I., & Johnson, B. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182745bcb · Cited by 112
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
Modjtahedi, H., Cho, B. C., Michel, M. C., & Solca, F. (2014) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-014-0967-3 · Cited by 109
The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272
Minami, Y., Shimamura, T., Shah, K., LaFramboise, T., Glatt, K. A., Liniker, E., Borgman, C. L., Haringsma, H. J., Feng, W. W., Weir, B. A., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210292 · Cited by 109
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene
Fukui, T., Yatabe, Y., Kobayashi, Y., Tomizawa, K., Ito, S., Hatooka, S., Matsuo, K., & Mitsudomi, T. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.03.013 · Cited by 109
Lung Cancer: Are we up to the Challenge?
Esposito, L., Conti, D., Ailavajhala, R., Khalil, N., & Giordano, A. (2010) · Current Genomics · doi:10.2174/138920210793175903 · Cited by 110
Patterns of EGFR, HER2, TP53 , and KRAS Mutations of p14arf Expression in Non–Small Cell Lung Cancers in Relation to Smoking History
Mounawar, M., Mukeria, A., Calvez‐Kelm, F. L., Hung, R. J., Renard, H., Cortot, A. B., Bollart, C., Zaridze, D. G., Brennan, P., Boffetta, P., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4229 · Cited by 108
Somatic mutations of theERBB4kinase domain in human cancers
Soung, Y. H., Lee, J. W., Kim, S. Y., Wang, Y. P., Jo, K. H., Moon, S. W., Park, W. S., Nam, S. W., Lee, J. Y., Yoo, N. J., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21507 · Cited by 107
EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy
Milanezi, F., Carvalho, S., & Schmitt, F. C. (2008) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.8.4.417 · Cited by 109
Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1/HER3 Pathway Activation
Endo, H., Okami, J., Okuyama, H., Kumagai, T., Uchida, J., Kondo, J., Takehara, T., Nishizawa, Y., Imamura, F., Higashiyama, M., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182779ccf · Cited by 109
Targeting HER2 Alterations in Non–Small-Cell Lung Cancer: A Comprehensive Review
Zhao, J., & Xia, Y. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00333 · Cited by 108
From cystic pulmonary airway malformation, to bronchioloalveolar carcinoma and adenocarcinoma of the lung
Ioachimescu, O. C., & Mehta, A. C. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00011705 · Cited by 107
Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic Features
Shibata, T., Uryu, S., Kokubu, A., Hosoda, F., Ohki, M., Sakiyama, T., Matsuno, Y., Tsuchiya, R., Kanai, Y., Kondo, T., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0293 · Cited by 104
The Impact of Genomic Changes on Treatment of Lung Cancer
Cardarella, S., & Johnson, B. E. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201305-0843pp · Cited by 103
Targeted Therapies for Lung Cancer
Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V., & Minna, J. D. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e701a · Cited by 106
Self-citation
Nonsmall cell lung carcinoma: diagnostic difficulties in small biopsies and cytological specimens
Bubendorf, L., Lantuéjoul, S., de Langen, A. J., & Thunnissen, E. (2017) · European Respiratory Review · doi:10.1183/16000617.0007-2017 · Cited by 102
The Genomics of Lung Adenocarcinoma: Opportunities for Targeted Therapies
Greulich, H. E. (2010) · Genes & Cancer · doi:10.1177/1947601911407324 · Cited by 109
Oncogenic Alterations in ERBB2/HER2 Represent Potential Therapeutic Targets Across Tumors From Diverse Anatomic Sites of Origin
Chmielecki, J., Ross, J. S., Wang, K., Frampton, G. M., Palmer, G. A., Ali, S. M., Palma, N. A., Morosini, D., Miller, V. A., Yelensky, R., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0234 · Cited by 101
Poziotinib for Patients With HER2 Exon 20 Mutant Non–Small-Cell Lung Cancer: Results From a Phase II Trial
Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Gibbons, D. L., Fossella, F. V., Lam, V. K. L., Patel, A. B., Negrao, M. V., Le, X., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01113 · Cited by 101
Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers
Lee, S. Y., Kim, M. J., Jin, G., Yoo, S. S., Park, J. Y., Choi, J. E., Jeon, H. S., Cho, S., Lee, E. B., Cha, S. I., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f0beca · Cited by 97
Lung Adenocarcinomas with HER2-Activating Mutations Are Associated with Distinct Clinical Features and HER2/EGFR Copy Number Gains
Li, C., Sun, Y., Fang, R., Han, X., Luo, X., Wang, R., Pan, Y., Hu, H., Zhang, Y., Pao, W. J., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318234f0a2 · Cited by 96
Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation
Blons, H., Côté, J.-F., Corre, D. L., Riquet, M., Fabre, E., Laurent‐Puig, P., & Danel, C. J. (2006) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213285.65907.31 · Cited by 93
Mutational activation of ErbB family receptor tyrosine kinases: insights into mechanisms of signal transduction and tumorigenesis
Riese, D. J., Gallo, R. M., & Settleman, J. E. (2007) · BioEssays · doi:10.1002/bies.20582 · Cited by 93
Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review
Köhler, J., & Schüler, M. (2013) · Oncology Research and Treatment · doi:10.1159/000354627 · Cited by 93
ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
Chuang, J. C., Stehr, H., Liang, Y., Das, M. S., Huang, J. Q., Diehn, M., Wakelee, H. A., & Neal, J. W. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.023 · Cited by 91
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
Grève, J. D., Morán, T., Graas, M.-P., Galdermans, D., Vuylsteke, P., Canon, J.-L. R., Schallier, D. C. C., Decoster, L., Teugels, E., Massey, D., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.013 · Cited by 91
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer
Bose, P., & Ozer, H. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903305428 · Cited by 89
The Role of DNA Methylation in the Development and Progression of Lung Adenocarcinoma
Kerr, K. M., Galler, J. S., Hagen, J. A., Laird, P. W., & Laird‐Offringa, I. A. (2007) · Disease Markers · doi:10.1155/2007/985474 · Cited by 90
Prognostic and predictive biomarkers in lung cancer. A review
Thunnissen, E., der Oord, K. V., & den Bakker, M. (2014) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-014-1535-4 · Cited by 92
Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
Herter-Sprie, G. S., Greulich, H. E., & Wong, K. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00086 · Cited by 88
Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers
Offin, M. D., Feldman, D., Ni, A., Myers, M. L., Lai, W. V., Pentsova, E. I., Boire, A. A., Daras, M., Jordan, E., Solit, D. B., et al. (2019) · Cancer · doi:10.1002/cncr.32461 · Cited by 89
Advances in Treatment of Lung Cancer With Targeted Therapy
Cagle, P. T., & Chirieac, L. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0618-ra · Cited by 89
Mutational Analysis of EGFR and Related Signaling Pathway Genes in Lung Adenocarcinomas Identifies a Novel Somatic Kinase Domain Mutation in FGFR4
Marks, J. L., McLellan, M. D., Zakowski, M. F., Lash, A., Kasai, Y., Broderick, S., Sarkaria, I. S., Ceppa, D. P., Singh, B., Miner, T. L., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000426 · Cited by 87
Combined Inactivation of MYC and K-Ras Oncogenes Reverses Tumorigenesis in Lung Adenocarcinomas and Lymphomas
Tran, P. T., Fan, A. C., Bendapudi, P. K., Koh, S., Komatsubara, K. M., Chen, J., Horng, G., Bellovin, D. I., Giuriato, S., Wang, C. S., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002125 · Cited by 87
Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
Estrada‐Bernal, A., Le, A. T., Doak, A. E., Tirunagaru, V. G., Silva, S., Bull, M. R., Smaill, J. B., Patterson, A. V., Kim, C., Liu, S. V., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3555 · Cited by 84
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program
Peters, S., Fontecedro, A. C., Nechushtan, H., Shih, J., Liao, W., Gautschi, O. P., Spataro, V. J., Unk, M., Yang, J. C., Lorence, R. M., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.07.093 · Cited by 85
Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
Shaurova, T., Zhang, L., Goodrich, D. W., & Hershberger, P. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00281 · Cited by 82
Targeting Protein Translation in Human Non–Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression
Legrier, M., Yang, C. H., Yan, H.-G., Lopez-Barcons, L. A., Keller, S. M., Perez-Soler, R., Horwitz, S. B., & McDaid, H. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0702 · Cited by 84
Advances in Target Therapy for Lung Cancer
Mitsudomi, T. (2009) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyp174 · Cited by 84
EGFR inhibitors: what have we learned from the treatment of lung cancer?
Giaccone, G., & Rodríguez, J. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0341 · Cited by 83
Targeted therapies in development for non-small cell lung cancer
Dy, G. K., & Reungwetwattana, T. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.123972 · Cited by 80
EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients
Bae, N. C., Chae, M. H., Lee, M. H., Kim, K. M., Lee, E. B., Kim, C. H., Park, T. I., Han, S. B., Jheon, S., Jung, T. H., et al. (2007) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.10.007 · Cited by 82
Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists
Rexer, B. N., Engelman, J. A., & Arteaga, C. L. (2009) · Cell Cycle · doi:10.4161/cc.8.1.7324 · Cited by 84
Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung
Marchetti, A., Felicioni, L., Pelosi, G., Grammastro, M. D., Fumagalli, C., Sciarrotta, M., Malatesta, S., Chella, A., Barassi, F., Mucilli, F., et al. (2008) · Human Mutation · doi:10.1002/humu.20707 · Cited by 80
Antitumor activity of HM781‐36B, a highly effective pan‐HER inhibitor in erlotinib‐resistant NSCLC and other EGFR‐dependent cancer models
Cha, M. Y., Lee, K., Kim, M., Song, J. Y., Lee, K. H., Park, J., Chae, Y. J., Kim, Y. H., Suh, K. H., Lee, G. S., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26276 · Cited by 80
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations
Iwama, E., Zenke, Y., Sugawara, S., Daga, H., Morise, M., Yanagitani, N., Sakamoto, T., Murakami, H., Kishimoto, J., Matsumoto, S., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.11.021 · Cited by 81
NSCLC and HER2: between lights and shadows
Ricciardi, G. R. R., Russo, A., Franchina, T., Ferraro, G., Zanghì, M., Picone, A., Scimone, A., & Adamo, V. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000379 · Cited by 78
Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study
Lai, W. V., Lebas, L., Barnes, T. A., Milia, J., Ni, A., Gautschi, O. P., Peters, S., Ferrara, R., Plodkowski, A. J., Kavanagh, J., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.11.030 · Cited by 79
Heat Shock Protein 90 Inhibition in Lung Cancer
Shimamura, T., & Shapiro, G. I. (2008) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318174ea3a · Cited by 79
Targeted therapy in NSCLC driven by HER2 insertions.
Peters, S., & Zimmermann, S. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.02.06 · Cited by 77
Epidermal growth factor receptor mutations in lung cancers
Yatabe, Y., & Mitsudomi, T. (2007) · Pathology International · doi:10.1111/j.1440-1827.2007.02098.x · Cited by 77
The ErbB kinase domain: Structural perspectives into kinase activation and inhibition
Bose, R., & Zhang, X. (2008) · Experimental Cell Research · doi:10.1016/j.yexcr.2008.07.031 · Cited by 78
Antitumor effect of afatinib, as a human epidermal growth factor receptor 2‐targeted therapy, in lung cancers harboring HER 2 oncogene alterations
Suzawa, K., Toyooka, S., Sakaguchi, M., Morita, M., Yamamoto, H., Tomida, S., Ohtsuka, T., Watanabe, M., Hashida, S., Maki, Y., et al. (2015) · Cancer Science · doi:10.1111/cas.12845 · Cited by 77
Self-citation
Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers
Hu, C., Zhao, L., Liu, W., Fan, S., Liu, J., Liu, Y., Liu, X., Shu, L., Liu, X., Liu, P., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003773 · Cited by 76
EGFR point mutation in non‐small cell lung cancer is occasionally accompanied by a second mutation or amplification
Yokoyama, T., Kondo, M., Gotô, Y., Fukui, T., Yoshioka, H., Yokoi, K., Osada, H., Imaizumi, K., Hasegawa, Y., Shimokata, K., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00233.x · Cited by 76
Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers
Wen, W., Chen, W., Xiao, N., Bender, R. P., Ghazalpour, A., Tan, Z., Swensen, J. J., Millis, S. Z., Basu, G. D., Gatalica, Z., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.04.003 · Cited by 76
Her2-Targeted Therapies in Non–Small Cell Lung Cancer
Swanton, C., Futreal, A., & Eisen, T. G. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0115 · Cited by 76
Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer
Zuo, W., Jiang, Y., Wang, Y.-J., Xu, X., Hu, X. Y., Liu, G., Wu, J., Di, G., Yu, K., & Shao, Z.-M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3036 · Cited by 76
Pulmonary adenocarcinoma: A renewed entity in 2011
Kadara, H. N., Kabbout, M., & Wistuba, I. I. (2011) · Respirology · doi:10.1111/j.1440-1843.2011.02095.x · Cited by 78
Self-citation
HER2 gene mutations in non-small cell lung carcinomas: Concurrence with her2 gene amplification and her2 protein expression and phosphorylation
Suzuki, M., Shiraishi, K., Yoshida, A., Shimada, Y., Suzuki, K., Asamura, H., Furuta, K., Kohno, T., & Tsuta, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.10.014 · Cited by 75
Self-citation
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
Cocco, E., Carmona, F. J., Razavi, P., Won, H. H., Cai, Y., Rossi, V., Chan, C., Cownie, J., Soong, J., Toska, E., et al. (2018) · Science Signaling · doi:10.1126/scisignal.aat9773 · Cited by 74
Lung Cancer, Smoke Exposure, and Sex
Gazdar, A. F., & Thun, M. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.4623 · Cited by 74
Self-citation
Genetic and epigenetic changes in lung carcinoma and their clinical implications
Wen, J., Fu, J., Zhang, W., & Guo, M. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.46 · Cited by 77
Biomarkers in Lung Adenocarcinoma: A Decade of Progress
Sholl, L. M. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2014-0128-ra · Cited by 75
Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2
Rexer, B. N., Ghosh, R., Narasanna, A., Estrada, M. V., Chakrabarty, A., Song, Y., Engelman, J. A., & Arteaga, C. L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1038 · Cited by 73
Patient‐derived xenograft model in cancer: establishment and applications
Gu, A., Li, J., Li, M., & Liu, Y. (2025) · MedComm · doi:10.1002/mco2.70059 · Cited by 82
Genomic Aberrations in Lung Adenocarcinoma in Never Smokers
Job, B., Bernheim, A., Beau‐Faller, M., Camilleri‐Broët, S., Girard, P., Hofman, P. M., Mazières, J., Toujani, S., Lacroix, L., Laffaire, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015145 · Cited by 75
Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications
Imperial, R. J. L., Toor, O. M., Hussain, A., Subramanian, J., & Masood, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.016 · Cited by 74
Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study
Koga, T., Kobayashi, Y., Tomizawa, K., Suda, K., Kosaka, T., Sesumi, Y., Fujino, T., Nishino, M., Ohara, S., Chiba, M., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.10.019 · Cited by 70
Self-citation
Impact of Common Epidermal Growth Factor Receptor and HER2 Variants on Receptor Activity and Inhibition by Lapatinib
Gilmer, T. M., Cable, L., Alligood, K. J., Rusnak, D. W., Spehar, G. M., Gallagher, K. T., Woldu, E., Carter, H. L., Truesdale, A. T., Shewchuk, L. M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2404 · Cited by 70
Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
Vermeij, J., Teugels, E., Bourgain, C., Ji, X., Veld, P. I. '., Ghislain, V., Neyns, B., & Grève, J. D. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-3 · Cited by 68
Uncommon V599E BRAF Mutations in Japanese Patients with Lung Cancer
Sasaki, H., Kawano, O., Endo, K., Suzuki, E., Haneda, H., Yukiue, H., Kobayashi, Y., Yano, M., & Fujii, Y. (2005) · Journal of Surgical Research · doi:10.1016/j.jss.2005.10.022 · Cited by 68
Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma
Tanaka, K., Hida, T., Oya, Y., Yoshida, T., Shimizu, J., Mizuno, T., Kuroda, H., Sakakura, N., Yoshimura, K., Horio, Y., et al. (2017) · Cancer · doi:10.1002/cncr.30539 · Cited by 68
SORLA regulates endosomal trafficking and oncogenic fitness of HER2
Pietilä, M., Sahgal, P., Peuhu, E., Jäntti, N. Z., Paatero, I., Närvä, E., Al-Akhrass, H., Lilja, J., Georgiadou, M., Andersen, O. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10275-0 · Cited by 75

Authors: Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., Fujisawa, T., Minna, J. D., & Gazdar, A. F.
Affiliations: Okayama University (JP)
1Hamon Center for Therapeutic Oncology Research, Departments of
Chiba University (JP)
Chung Shan Medical University (TW)
The University of Texas MD Anderson Cancer Center (US)
Prince Charles Hospital (AU)
The University of Texas Southwestern Medical Center (US)
ORCID: Majmudar, Kuntal
Suzuki, Makoto
Wistuba, Ignacio I.
Fong, Kwun M.
Toyooka, Shinichi
Minna, John D.
Gazdar, Adi F.
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2005-03-01
Volume: 65
Issue: 5
Pages: 1642-1646
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-04-4235
OpenAlex: W2133867160
Cited by: 678
References: 28
Citations by year: 2026: 8 · 2025: 17 · 2024: 13 · 2023: 18 · 2022: 16 · 2021: 36 · 2020: 29 · 2019: 27 · 2018: 36 · 2017: 23 · 2016: 27 · 2015: 46 · 2014: 46 · 2013: 54 · 2012: 34
FWCI: 42.08
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute ((P50-CA70907, P50CA070907, 5U01 CA 8497102)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: HER2 mutation, lung adenocarcinoma, non-small cell lung cancer, EGFR mutation, KRAS mutation, tyrosine kinase domain, never smokers, ethnic differences in mutation frequency, lung cancer etiology, EGFR kinase inhibitors
MeSH terms: Adenocarcinoma, Aged, Aged, 80 and over, Amino Acid Sequence, Female, Humans, Lung Neoplasms, Male, Middle Aged, Molecular Sequence Data, Mutation, Neoplasms, Glandular and Epithelial, Genes, ras, Sequence Homology, Amino Acid, Genes, erbB-2, Genes, erbB-1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Somatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks